Study Highlights Disparities in Genetic Testing in Ovarian and Breast Cancer

A study of genetic testing in ovarian and breast cancer patients found substantial disparities in testing rates for ovarian cancer patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

AbstractPurpose of ReviewThe consequence of treatment for gynaecological cancers can cause sudden onset of intense menopausal symptoms, such as vasomotor symptoms, sexual dysfunction and emotional instability. Hormone replacement therapy (HRT) is often effective and can overcome these unpleasant and severe symptoms. However, data regarding its safety remains controversial. The big question therefore is whether HRT in gynaecological cancer survivors is possible. This is due to the fear of disease relapse. So, the purpose of this study was to review the evidence regarding cancer recurrence or death following use of HRT in su...
Source: Current Obstetrics and Gynecology Reports - Category: OBGYN Source Type: research
ConclusionsBack-to-back random-start ovarian stimulation may be an effective way to maximize fertility preservation, even in time-limited settings.
Source: Journal of Assisted Reproduction and Genetics - Category: Reproduction Medicine Source Type: research
Authors: Telli ML, Gradishar WJ, Ward JH Abstract Advances in molecular testing have ushered in the new era of precision medicine. The 2018 publication of the TAILORx trial helped refine the use of genetic expression assays, specifically the 21-gene recurrence score, in assigning patients to endocrine therapy alone or with chemotherapy. The NCCN Guidelines for Breast Cancer explore the clinical applications of this study. The algorithm for managing the axilla in early breast cancer has been further refined, based on the presence or absence of clinical evidence of lymph node involvement. Ovarian suppression has been...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
This study investigates the effect of reduced BRCA1 expression on proliferation and NFκB activation in human breast cells, and the impact of progesterone on these effects. The major findings are that: 1) Reduced BRCA1 levels inhibit cell growth in normal human mammary cells and breast cancer cells; 2) Reduced BRCA1 levels stimulated i nflammatory targets and NFκB activity in normal human mammary cells; 3) Wildtype BRCA1 inhibited the pro-proliferative effects of progesterone in normal mammary epithelial cells, and; 4) Progesterone attenuated BRCA1-mediated NFκB activation in normal human mammary cells. Th...
Source: Journal of Mammary Gland Biology and Neoplasia - Category: Cancer & Oncology Source Type: research
Debulking surgery, followed by taxane/platinum-based chemotherapy has traditionally been the first-line treatment for advanced ovarian cancer. However, most patients will experience recurrence afterwards, and receive subsequent lines of therapy. It has been proposed that extending the treatment-free interval of platinum can improve the response to a subsequent platinum-based chemotherapy, and reduce associated toxicities in women with recurrent, platinum-sensitive ovarian cancer. The aim was to determine the impact, in clinical practice, of trabectedin with pegylated liposomal doxorubicin (trabectedin/PLD) on the subsequen...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: CLINICAL REPORT Source Type: research
Authors: Rodgers RJ Abstract Breast cancer is the most commonly diagnosed cancer in women. As long-term survival rates have improved, there has been a concurrent increase in quality of life considerations, of which fertility preservation is of utmost importance. A number of fertility preservation options are available to women diagnosed with breast cancer, including administration of a GnRH agonist during chemotherapy in an attempt to minimize ovarian damage, oocyte or embryo cryopreservation prior to the administration of chemotherapy, in vitro maturation of oocytes or ovarian tissue cryopreservation. The safety o...
Source: Minerva Ginecologica - Category: OBGYN Tags: Minerva Ginecol Source Type: research
Mesothelin is a cell surface protein that is an excellent target for immunotherapy because of its limited expression on normal tissues and its high expression on many cancers, including mesothelioma, cholangiocarcinoma, pancreatic, ovarian, lung, stomach, bile duct, and triple-negative breast cancer.Researchers at the National Cancer Institute ’s (NCI)Laboratory of Molecular Biology have isolated two anti-mesothelin single domain antibodies (also known as nanobodies), A101 and G8. These antibodies have been isolated from newly developed camel single domain (VHH) libraries by phage display and have been used to shown ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Publication date: Available online 14 May 2019Source: Pathology - Research and PracticeAuthor(s): Jie Mei, Yifu Huang, Leiyu Hao, Yan Liu, Ting Yan, Tonglu Qiu, Rui Xu, Bujie Xu, Zhuang Xiao, Xiaozheng Jiang, Kehan Hu, Yichao ZhuAbstractOvarian cancer (OvCa) has the highest morbidity among all gynecologic cancers worldwide, and its distant metastasis is one of main causes for the poor prognosis of OvCa patients. Our previous studies have reported that DAAM1-involved signaling pathways play vital roles in metastasis of breast cancer. However, whether DAAM1 participates in OvCa migration and/or invasion is still unknown. The...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Women found to have mutations of the BrCa 1 or 2 genes face many therapeutic decisions with respect to prevention of ovarian and breast cancer and management of menopausal symptoms after natural or surgical menopause. The first issue is whether these women should undergo breast cancer prevention with an antiestrogen. This issue predominantly affects pre-menopausal women. The majority of data suggest that tamoxifen reduces the risk of breast cancer by approximately 50% of women with these two mutations (RR 0.38 –0.50 for BrCa1 and 0.42–0.63 for BrCa2).
Source: Maturitas - Category: Primary Care Authors: Tags: INV31 Source Type: research
Abstract Ovarian cancer (OvCa) has the highest morbidity among all gynecologic cancers worldwide, and its distant metastasis is one of main causes for the poor prognosis of OvCa patients. Our previous studies have reported that DAAM1-involved signaling pathways play vital roles in metastasis of breast cancer. However, whether DAAM1 participates in OvCa migration and/or invasion is still unknown. The impact of DAAM1 on cell migration and invasion in OvCa was evaluated by wound healing assay and Boyden chamber assay. The specific miRNA targeting DAAM1 was predicted by bioinformatics methods and verified by dual-luci...
Source: Pathology, Research and Practice - Category: Pathology Authors: Tags: Pathol Res Pract Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Ovarian Cancer | Ovaries | Study